Citron Provides New Proof Why Mallinckrodt is on its way to ZERO

, , , ,

Express Scripts lets the genie out the bottle!!!!

When Jim Chanos Speaks – Citron Listens.

First Enron, Then Valeant, Now Mallinckrodt.


Mallinckrodt is the most reviled company in the pharmaceutical industry.  Its unsavory business practices have only survived in the “post Valeant” era because of the direct business support of Express Scripts, their “co-conspirator”.

Two weeks ago at the SALT conference in Las Vegas, legendary short seller Jim Chanos described this unholy alliance, likening the Express Scripts companies’ role to Valeant’s Philidor.

Express Scripts has been taking so much heat from investors it was forced to throw Mallinckrodt under the bus.  But a typo prevented Wall Street from taking full notice of this sea change in Mallinckrodt’s fortunes.

For the rest of the story you won’t read anywhere else, Click Here: 


Mallinckrodt CEO FRAUD exposed by the new Medicare Drug Dashboard

, , , ,

Mallinckrodt Stock Target Price – $20


Dear Readers,

It has taken too much time but now the truth is out about Mallinckrodt ($MNK). The newly published Medicare dashboard proves that:

1.  As insurance companies have clamped down on reimbursement, tax-inverted Mallinckrodt has dug deeper into the pockets of taxpayer-funded Medicare to peddle its medically unproven Acthar

2. The CEO of MNK has committed FRAUD by lying to the investing public about the company’s dependence on the Medicare system.

3. Acthar is now THE MOST EXPENSIVE drug reimbursed by Medicare.

This will soon end and $MNK will trade at $20 a share

For the Rest of the Story You Won’t Read Anywhere Else … Click Here 

Cautious Investing To All

Questcor is Deceiving the FDA and Investors

, , ,

Citron Reports Further Results from Laboratory Testing:

Questcor is Deceiving the FDA and Investors

H.P. Acthar Gel’s Specified Active Ingredient Less Than 20% of the Label Specification

Bioactivity of Deamidated Hormone Fragment Far Lower than Pure ACTH

The FDA has been Notified

Citron reports on further lab data submitted to FDA, that the contents Questcor’s only revenue-generating drug product, H.P. Acthar Gel, does not match its label or the official product insert the label.  Questcor spins one story for Wall Street, and another for the medical community, but the regulatory risk here cannot be overstated.  

For the Full Story, Click Here:

(As always, Citron recommends that you download the .PDF file locally, and click to follow the links.)

Citron Comments on Questcor’s Non-Responsive Response

, , ,

Yesterday, Citron published independent laboratory findings on the active ingredient in Questcor’s only drug, Acthar Gel.  Today the company’s only response to these findings has now been quoted in Bloomberg.

Citron is astonished at what they didn’t say.

Click Here to Read our Comments on the Company’s Response


Questcor in Cover-Up Mode: Deleting Evidence from its Website … BUT Citron Finds the Smoking Gun and Presents it Here for the Federal Trade Commission. Investors please don’t read further — you might find something you don’t like.

, , ,

Over the coming months, Citron Research will release a series of articles on Questcor (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”.  These articles will dig deeper into topics such as:

·         The Chronic Disease Fund, and the role it plays in contributing to Questcor’s revenues

·         Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)

·         Insurance reimbursement coding for Acthar

Meanwhile, today’s question is whether Questcor’s Synacthen acquisition is anti-competitive.  The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.

We are sure that Questcor will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel.  This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.  

For the full story you won’t find anywhere else, click here!

( Citron as always recommends downloading the PDF for local viewing, and clicking on the links.)